

To: [redacted]@minvws.nl [redacted]@minvws.nl
Cc: [redacted]@pm.gouv.fr [redacted]@pm.gouv.fr;
 [redacted]@aemps.es [redacted]@aemps.es; [redacted]@rivm.nl [redacted]@rivm.nl;
 [redacted]@minvws.nl [redacted]@minvws.nl; [redacted]@ec.europa.eu [redacted]@ec.europa.eu]
From: [redacted]@ec.europa.eu
Sent: Wed 7/29/2020 3:38:43 PM
Subject: RE: Dutch Science Board Considerations and Recommendations on mRNA-based COVID-19 vaccine candidates
Received: Wed 7/29/2020 3:38:47 PM

Dear [redacted]

Gratefully received, thank you very much indeed also to [redacted] for this very prompt transmission.

With best regards,

[redacted]

Dr [redacted], DrPH

[redacted]



European Commission
 DG SANTE
 Unit B2
 B232 09/11
 B-1049 Brussels/Belgium
 +32 [redacted]
 [redacted]@ec.europa.eu

Follow us on Twitter:

@EU_Health @Food_EU

From: [redacted] <[redacted]@minvws.nl>
Sent: Wednesday, July 29, 2020 5:13 PM
To: [redacted] (SANTE) <[redacted]@ec.europa.eu>
Cc: [redacted]@pm.gouv.fr; [redacted]@aemps.es; [redacted] <[redacted]@rivm.nl>; [redacted] <[redacted]@minvws.nl>
Subject: FW: Dutch Science Board Considerations and Recommendations on mRNA-based COVID-19 vaccine candidates

Dear [redacted]

Please find attached the written opinion of the Dutch Scientific Board on mRNA vaccine candidates as announced.
 I think you have our contributions now.

Kind regards,

[redacted]

[redacted]

[redacted]

Dubbel

2 - 2

Dubbel